Biomarkers for neurodegenerative diseases

The cortical origin and initial spread of medial temporal tauopathy in Alzheimer’s disease assessed with positron emission tomography

(2021) Justin S. Sanchez et al.   Science Translational Medicine

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

(2021) Oskar Hansson et al.   Alzheimers & Dementia

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

(2021) Niklas Mattsson‐Carlgren et al.   EMBO Molecular Medicine

Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling study

(2021) Ming-Kai Chen et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Four distinct trajectories of tau deposition identified in Alzheimer’s disease

(2021) Jacob W. Vogel et al.   NATURE MEDICINE

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

(2021) Claudia Cicognola et al.   Alzheimers Research & Therapy

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

(2021) Sebastian Palmqvist et al.   NATURE MEDICINE

A multicentre validation study of the diagnostic value of plasma neurofilament light

(2021) Nicholas J. Ashton et al.   Nature Communications

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease

(2021) Rik Ossenkoppele et al.   JAMA Neurology

Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status

(2020) June Kaplow et al.   Alzheimers & Dementia

Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging

(2020) David Matuskey et al.   ANNALS OF NEUROLOGY

Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia

(2020) Carolin Heller et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy

(2020) Mohammad Shahnawaz et al.   NATURE

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Blood neurofilament light levels segregate treatment effects in multiple sclerosis

(2020) Bénédicte Delcoigne et al.   NEUROLOGY

Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET

(2020) Renaud La Joie et al.   Science Translational Medicine

Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease

(2020) Nicolai Franzmeier et al.   Nature Communications

Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies

(2020) Marcello Rossi et al.   ACTA NEUROPATHOLOGICA

In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET

(2020) Adam P. Mecca et al.   Alzheimers & Dementia

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   NATURE MEDICINE

Protein transmission in neurodegenerative disease

(2020) Chao Peng et al.   Nature Reviews Neurology

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

(2020) Shorena Janelidze et al.   Nature Communications

Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

(2020) Adam S. Fleisher et al.   JAMA Neurology

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

(2020) Antoine Leuzy et al.   JAMA Neurology

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   Science Advances

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Alpha‐Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies

(2020) Wolfgang Singer et al.   ANNALS OF NEUROLOGY

18F-MK-6240 PET for early and late detection of neurofibrillary tangles

(2020) Tharick A Pascoal et al.   BRAIN

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study

(2020) Antoinette O’Connor et al.   MOLECULAR PSYCHIATRY

Multi-tracer model for staging cortical amyloid deposition using PET imaging

(2020) Lyduine E. Collij et al.   NEUROLOGY

Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study

(2020) Michael J. Pontecorvo et al.   EJNMMI Research

Comparing progression biomarkers in clinical trials of early Alzheimer’s disease

(2020) Nicholas C. Cullen et al.   Annals of Clinical and Translational Neurology

Predicting future rates of tau accumulation on PET

(2020) Clifford R Jack et al.   BRAIN

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   BRAIN

Cryo-EM structures of tau filaments

(2020) Sjors HW Scheres et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

A Comprehensive View on MRI Techniques for Imaging Blood-Brain Barrier Integrity

(2020) Elles P. Elschot et al.   INVESTIGATIVE RADIOLOGY

Towards early disease modification of Parkinson’s disease: a review of lessons learned in the Alzheimer field

(2020) Marthe Smedinga et al.   JOURNAL OF NEUROLOGY

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

(2020) Thomas K. Karikari et al.   MOLECULAR PSYCHIATRY

Blinded RT‐QuIC Analysis of α‐Synuclein Biomarker in Skin Tissue from Parkinson's Disease Patients

(2020) Sireesha Manne et al.   MOVEMENT DISORDERS

Evaluation of a novel immunoassay to detect p-Tau Thr127 in the CSF to distinguish Alzheimer disease from other dementias

(2020) Jozef Hanes et al.   NEUROLOGY

Translating genetic risk of Alzheimer’s disease into mechanistic insight and drug targets

(2020) Annerieke Sierksma et al.   SCIENCE

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

(2020) Inge M. W. Verberk et al.   Alzheimers Research & Therapy

Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease

(2020) Zerui Wang et al.   JAMA Neurology

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects

(2020) Ruben Smith et al.   BRAIN

CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease

(2020) Kanta Horie et al.   BRAIN

Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease

(2020) Hendrik Wesseling et al.   CELL

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

(2020) Shorena Janelidze et al.   JAMA Neurology

Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction

(2019) Daniel A. Nation et al.   NATURE MEDICINE

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

(2019) Oliver Preische et al.   NATURE MEDICINE

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease

(2019) Rik Ossenkoppele et al.   NEUROLOGY

Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease

(2019) Un Jung Kang et al.   MOVEMENT DISORDERS

Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report

(2019) Peter T Nelson et al.   BRAIN

A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia

(2019) Michael J Pontecorvo et al.   BRAIN

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

(2019) Gil D. Rabinovici et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

NFL is a marker of treatment response in children with SMA treated with nusinersen

(2019) Bob Olsson et al.   JOURNAL OF NEUROLOGY

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

(2019) Oskar Hansson et al.   Alzheimers Research & Therapy

CSF and blood biomarkers for Parkinson's disease

(2019) Lucilla Parnetti et al.   LANCET NEUROLOGY

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

(2019) Sebastian Palmqvist et al.   JAMA Neurology

Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography

(2019) Niklas Mattsson et al.   JAMA Neurology

The neuropathological diagnosis of Alzheimer’s disease

(2019) Michael A. DeTure et al.   Molecular Neurodegeneration

Validation of the movement disorder society criteria for the diagnosis of 4‐repeat tauopathies

(2019) Gesine Respondek et al.   MOVEMENT DISORDERS

Brain-First versus Gut-First Parkinson’s Disease: A Hypothesis

(2019) Per Borghammer et al.   Journal of Parkinsons Disease

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

(2019) Sebastian Palmqvist et al.   EMBO Molecular Medicine

Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology

(2019) Kaj Blennow et al.   BRAIN

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays

(2019) Kaj Blennow et al.   Scientific Reports

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology

(2018) Erik Portelius et al.   ACTA NEUROPATHOLOGICA

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

(2018) Oskar Hansson et al.   Alzheimers & Dementia

Combined neuropathological pathways account for age-related risk of dementia

(2018) Melinda C. Power et al.   ANNALS OF NEUROLOGY

Longitudinal tau PET in ageing and Alzheimer’s disease

(2018) Clifford R Jack et al.   BRAIN

Secondary nucleation in amyloid formation

(2018) Mattias Törnquist et al.   CHEMICAL COMMUNICATIONS

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study

(2018) Brian A Gordon et al.   LANCET NEUROLOGY

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals

(2018) Heidi I. L. Jacobs et al.   NATURE NEUROSCIENCE

Tau Kinetics in Neurons and the Human Central Nervous System

(2018) Chihiro Sato et al.   NEURON

Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment

(2018) David A. Wolk et al.   JAMA Neurology

Plasma amyloid as pre-screener for the earliest Alzheimer's pathological changes

(2018) Inge M.W. Verberk et al.   ANNALS OF NEUROLOGY

Biomarkers for Alzheimer's disease: current status and prospects for the future

(2018) K. Blennow et al.   JOURNAL OF INTERNAL MEDICINE

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease

(2018) Leslie M. Shaw et al.   Alzheimers & Dementia

Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) Emma Nichols et al.   LANCET NEUROLOGY

Biomarkers for tau pathology

(2018) Michael Schöll et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology

(2018) Ruben Smith et al.   JAMA Neurology

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons

(2017) Michael C. Donohue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis

(2017) Giovanni Rizzo et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging

(2017) Anne Maass et al.   JOURNAL OF NEUROSCIENCE

Amyotrophic lateral sclerosis

(2017) Michael A van Es et al.   LANCET

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Niklas Mattsson et al.   NEUROBIOLOGY OF AGING

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype

(2017) Shorena Janelidze et al.   NEUROBIOLOGY OF AGING

Diagnosis and management of dementia with Lewy bodies

(2017) Ian G. McKeith et al.   NEUROLOGY

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

(2017) Sebastian Palmqvist et al.   Nature Communications

Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials

(2016) Jeff Sevigny et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum

(2016) Hanna Cho et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease

(2016) Rik Ossenkoppele et al.   BRAIN

The Cellular Phase of Alzheimer’s Disease

(2016) Bart De Strooper et al.   CELL

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Accuracy of clinical diagnosis of Parkinson disease

(2016) Giovanni Rizzo et al.   NEUROLOGY

Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases

(2016) Heiko Braak et al.   Cold Spring Harbor Perspectives in Biology

Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies

(2016) Graham Fairfoul et al.   Annals of Clinical and Translational Neurology

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Medical costs of Alzheimer's disease misdiagnosis among US Medicare beneficiaries

(2015) Craig A. Hunter et al.   Alzheimers & Dementia

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

(2015) Osama Sabri et al.   Alzheimers & Dementia

Tau positron emission tomographic imaging in aging and early Alzheimer disease

(2015) Keith A. Johnson et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease

(2015) Erik Portelius et al.   BRAIN

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lewy body dementias

(2015) Zuzana Walker et al.   LANCET

Frontotemporal dementia

(2015) Jee Bang et al.   LANCET

Parkinson's disease

(2015) Lorraine V Kalia et al.   LANCET

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density

(2015) Craig Curtis et al.   JAMA Neurology

Alzheimer's disease

(2015) Colin L. Masters et al.   Nature Reviews Disease Primers

Primary age-related tauopathy (PART): a common pathology associated with human aging

(2014) John F. Crary et al.   ACTA NEUROPATHOLOGICA

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

(2013) Keith A. Johnson et al.   Alzheimers & Dementia

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

(2012) Thomas G. Beach et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

(2012) Christopher M Clark et al.   LANCET NEUROLOGY

100 years of Lewy pathology

(2012) Michel Goedert et al.   Nature Reviews Neurology

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

(2011) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

Mild Cognitive Impairment

(2011) Ronald C. Petersen   NEW ENGLAND JOURNAL OF MEDICINE

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

(2011) Randall J Bateman et al.   Alzheimers Research & Therapy

Missed and Delayed Diagnosis of Dementia in Primary Care

(2010) Andrea Bradford et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Imaging Approaches to Parkinson Disease

(2010) D. J. Brooks   JOURNAL OF NUCLEAR MEDICINE

Age, Neuropathology, and Dementia

(2009) George M. Savva et al.   NEW ENGLAND JOURNAL OF MEDICINE

Measuring target effect of proposed disease-modifying therapies in Alzheimer’s disease

(2008) Randall J. Bateman et al.   Neurotherapeutics